Danaher CEO targets 4% to 5% core growth by 2027
Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash
Danaher's new CEO Julie Sawyer Montgomery, speaking at the UBS Global Healthcare Conference, set a 2027 target of 4% to 5% core growth excluding respiratory, with aspirations for high-single-digit growth over the long term. The plan leans on commercial execution, innovation, talent and disciplined capital allocation, focused on AI drug discovery, diagnostics, Cytiva and China.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.